CN107789480A - A kind of pharmaceutical composition for being used to treat canker sore - Google Patents
A kind of pharmaceutical composition for being used to treat canker sore Download PDFInfo
- Publication number
- CN107789480A CN107789480A CN201610754644.9A CN201610754644A CN107789480A CN 107789480 A CN107789480 A CN 107789480A CN 201610754644 A CN201610754644 A CN 201610754644A CN 107789480 A CN107789480 A CN 107789480A
- Authority
- CN
- China
- Prior art keywords
- extract
- pharmaceutical composition
- canker sore
- parts
- chitosan
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/27—Asclepiadaceae (Milkweed family), e.g. hoya
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/535—Perilla (beefsteak plant)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8969—Polygonatum (Solomon's seal)
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a kind of pharmaceutical composition for being used to treat canker sore, the new pharmaceutical composition is made up of the composition of following weight：10 parts of chitosan oligomer 3 part, 2 parts of Fructus Fici extract 0.5 part, 1 part of cajan seed extract 0.5 part, 1 part of Rhizoma Polygonati Odorati extract 0.5 part, 0.75 part of common perilla seed extract 0.25 part, 0.75 part of South Mountain boisiana extract 0.25 part.This pharmaceutical composition carries out acute toxicity testing, as a result shows that the pharmaceutical composition of the present invention can be considered nontoxic；Wound repair experiment is carried out, it was demonstrated that the surface of a wound heals substantially, without obvious scar；Zoopery explanation has significant effect to treatment canker sore.Therefore, pharmaceutical composition of the invention can be used for treating canker sore, there is larger clinical value and social benefit.Preparation method of the present invention is simple, is suitable for industrialized production.
Description
Technical field
The present invention relates to pharmaceutical composition, and in particular to a kind of pharmaceutical composition for being used to treat canker sore.
Background technology
At present, based on the research to chitosan, having reported it has promotion wound, antibacterial, antitumor, Adjust-blood lipid, tune
The multiple functions such as immune are saved, but because of its poorly water-soluble, greatly limit its application in life and health field.The present inventor passes through
Enzyme edman degradation Edman, by degradation of chitosan into the degree of polymerization is small, water-soluble big chitosan oligomer.
It is verified by experiments, the sugar chain structure of chitosan oligomer is highly similar to the surface texture of cell membrane, has very to cell
Good affinity, the effect such as identification, information reception and registration, contact inhibition is played in iuntercellular；And chitosan oligomer can be acted on directly
In cell surface, play a part of repairing damaged cell, so as to recover the function of cell, promote wound healing.
However, the present inventor further study show that, such as individually by chitosan oligomer be used for treat canker sore when, effect
Not significantly, when adding other compositions pharmaceutical composition is made, to treating canker sore positive effect.Thus, preferably actively grind
Study carefully oligopolymerization chitosan sugar composite and its new indication.
The content of the invention
The technical problems to be solved by the invention are to overcome above-mentioned weak point, medicine of the research and design containing chitosan oligomer
Compositions and its clinical practice.
The invention provides a kind of pharmaceutical composition for being used to treat canker sore.
The pharmaceutical composition of the present invention is made up of the composition of following weight：3 parts -10 parts of chitosan oligomer, no flower
0.5 part -2 parts of berry extract, 0.5 part -1 part of cajan seed extract, 0.5 part -1 part of Rhizoma Polygonati Odorati extract, 0.25 part of common perilla seed extract -
0.75 part, 0.25 part -0.75 part of South Mountain boisiana extract.
Preferably, pharmaceutical composition of the invention is made up of the composition of following weight proportion：5 parts of chitosan oligomer, no flower
1 part of berry extract, 0.8 part of cajan seed extract, 0.8 part of Rhizoma Polygonati Odorati extract, 0.5 part of common perilla seed extract, South Mountain boisiana extract 0.5
Part.
It is a further object of the present invention to provide the preparation method of described pharmaceutical composition, this method is：
Chitosan oligomer, Fructus Fici extract, cajan seed extract, Rhizoma Polygonati Odorati extract, common perilla seed extract, South Mountain boisiana extract with
Water is mixed together, and being sufficiently stirred makes it uniformly boil 5min, be cooled to 25 DEG C ± 2 DEG C of room temperature, be filtered to remove insoluble matter, produce.
In pharmaceutical composition of the present invention, the mean molecule quantity of the chitosan oligomer is 500-3000, by following
It is prepared by method：
Chitosan 10g acetic acid 333ml are dissolved, chitosan concentration 0.03g/ml, add bromelain 5ml（Containing enzyme amount
40u）Hydrolysis, hydrolyze 20mim after adjust pH value to 6.0,50 DEG C continue degrade 5h, 100 DEG C of enzyme deactivation 15min, centrifuging and taking supernatant,
Freeze-drying, obtains chitosan oligomer 9.23g.Tested through HPLC, confirm as chitosan oligomer, mean molecule quantity 1100.
The originals such as the Fructus Fici extract, cajan seed extract, Rhizoma Polygonati Odorati extract, common perilla seed extract, South Mountain boisiana extract
Material is by being commercially available.
It is yet another object of the invention to provide described pharmaceutical composition to prepare the application in treating stomatocace medicine.
The present inventor has carried out acute toxicity testing to described pharmaceutical composition, as a result shows the pharmaceutical composition of the present invention
It can be considered nontoxic；Wound repair experiment is carried out, it was demonstrated that the surface of a wound heals substantially, without obvious scar；Zoopery explanation is to treatment
Canker sore has significant effect.Thus, pharmaceutical composition of the invention can be used for preparing treatment stomatocace medicine.
The pharmaceutical composition of the present invention solves the problems, such as that canker sore is difficult to healing, and pharmaceutical composition of the present invention is nontoxic
Property, significant effect, there are larger clinical value and social benefit for treating canker sore.Preparation method letter of the present invention
It is single, it is suitable for industrialized production.
Embodiment
The preparation of the chitosan oligomer of embodiment 1（Enzyme process）.
By chitosan 10g（Degree of deacetylation 95%, moisture 4.85%, ash content 0.5%, viscosity average molecular weigh 100,000, purchased from Jinan
Hai get Bei ocean engineerings Co., Ltd）Dissolved with acetic acid 333ml, chitosan concentration 0.03g/ml, add bromelain 5ml
（40u containing enzyme amount）Hydrolysis, hydrolyze 20mim after adjust pH value to 6.0,50 DEG C continue degrade 5h, 100 DEG C of enzyme deactivation 15min, centrifuging and taking
Supernatant, freeze-drying, obtains chitosan oligomer 9.23g.Tested through HPLC, confirm as chitosan oligomer, mean molecule quantity is
1100。
The preparation of the pharmaceutical composition of embodiment 2.
Chitosan oligomer purity >=98%, mean molecule quantity 1100, embodiment 1 are made.
Following composition raw material is commercially available：
Fructus Fici extract fig polysaccharide content >=15%；
Cajan seed extract pigeonpea general flavone content >=20%；
Rhizoma Polygonati Odorati extract radix polygonati officinalis general flavone content >=20%；
Common perilla seed extract Perilla frutescens general flavone content >=10%；
South Mountain boisiana extract Wattakaka sinensis Stapf general flavone content >=10%.
200ml beakers are taken, 100ml is added and removes thermal source distilled water, then add 5g chitosan oligomers, the extraction of 1g figs
Thing, 0.8g cajan seed extracts, 0.8g Rhizoma Polygonati Odorati extracts, 0.5g common perillas seed extract, 0.5g South Mountain boisiana extract, being sufficiently stirred makes
It is well mixed, boils 5min, is cooled to 25 DEG C of room temperature, is filtered to remove insoluble matter, produce pharmaceutical composition 108.9g.
Pharmaceutical composition made from embodiment 2 is used for following experiments.
The acute toxicity testing of embodiment 3.
Experimental animal：Kunming mice 70,17 ~ 22g of body weight, male and female half and half are limited purchased from Shanghai Si Laike experimental animals
Company.
Animal packet：Distinguish the Stochastic Equilibrium method of dividision into groups using male and female, be divided into 7 groups, every group 10, one of which is blank
Control group.
Laboratory sample：It is made in embodiment 2.
Dosage determines：Dose design is 3ml/kg, 10ml/kg, 50ml/kg, 100ml/kg.
Administration：Disposable gastric infusion：3 ~ 5h of fasting before administration, after administration 1 ~ 2h of fasting, fasting can't help water.Using in batches
Administration, control group, 3ml/kg groups, 10ml/kg groups first administrations, determined after administration set by dosage it is suitable, then give 50ml/kg
Group and 100ml/kg groups.Continuous Observation more than 7 days after administration, then morning and afternoon is respectively observed once daily, Continuous Observation 14 days.In detail
Every observation index is carefully recorded, is shown in Table 1.
Table 1.
Conclusion：Tested material is when gastric infusion dosage reaches 100ml/kg in this experiment（Solid equivalent to 5.5mg/kg
Medicine）, do not occur death.Judge according to acute toxicity grading criteria, this test medicine can be considered nontoxic.
The wound repair of embodiment 4 is tested.
Experimental animal：C57 mouse, 16-18g, male, purchased from Shanghai Slac Experimental Animal Co., Ltd..
Test method：Test mice is divided into blank group, control group 1（U.S.'s 3M medical adhesive tapes）, control group 2（Britain applies
Expensive precious Convatee products）, control group 3（Golden English peptide EGF）, experimental group, every group 20.Mouse back unhairing otch modeling, wound
Face iodophor disinfection, then with appropriate physiological saline debridement, then cover the product of control group 1, the product of control group 2 on surface；
The product of control group 3 and experimental group medicine are sprayed, spontaneously dries, is finally covered with sterile gauze.Respectively with regard to 3 days, 7 days and 14 days
Wound recovery situation is compareed.Experimental result is shown in Table 2.
Table 2.
Conclusion：Each item data of experimental group is significantly better than control group and blank group.
The cell proliferation test of embodiment 5.
Cell line：People's epidermis protein cell line colo-16.
Culture medium：DMEM, containing 10% hyclone, 100 μ g/ml penicillin, 100 μ g/ml streptomysin；MTT, before use
The solution of 5mg/ml concentration is made into PH 7.2 PBS.
It is inoculated with epidermal cell：When the colo-16 cell growths of culture are close to individual layer, upper feelings liquid in bottle is drawn, with 0.3% pancreas
Protease digestion, add appropriate DMEM that cell monolayer suspension is made, be inoculated in 96 orifice plates, per the μ L of hole 200, put 37 degree of 5% dioxy
Change carbon incubator culture.
Drug-treated：After inoculation 24 hours, each hole supernatant and non-attached cell are drawn, is separately added into control group 1（Pacify skin
Relax）, control group 2（Golden English peptide EGF）, after experimental group, continue culture 3 days, cell proliferative conditions observed under inverted microscope.Knot
Fruit is shown in Table 3.
Table 3.
Conclusion：Experimental group cell proliferating number amount is substantially better than control group.
The zoopery of embodiment 6.
Animal：SD rats 60, female, 180~220g of body weight, purchased from Shanghai Slac Experimental Animal Co., Ltd..
Reagent：Carbolic acid.
Equipment：Glass tube, assay balance, microscope, syringe etc..
Establish experimental Oral ulcer model：Take SD rats 60, the glass tube for being 2mm with bottom diameter, built-in small cotton
Ball, cotton pellet bottom is put down with mouth under glass, 90% coal acid solution is then instilled in pipe untill just cotton pellet is impregnated with, so
After be placed on the inside of rat oral cavity lower lip and burn 45s on cheek mucous membrane, be partially formed canker sore after 24h.
Experimental method：Using water melon frost, xilei san as control, using pharmaceutical composition as experimental group, 20 rats are respectively taken, are observed
The ulcer healing situation of 1-4 days.Experimental result is shown in Table 4.
Table 4.
Conclusion：Experimental group ulcer healing situation is substantially better than control group, illustrates that Experimental agents composition is burst to treatment oral cavity
Ulcer is evident in efficacy.
Claims (8)
1. a kind of pharmaceutical composition for being used to treat canker sore, it is characterised in that described pharmaceutical composition is by following parts by weight
The composition composition of proportioning：3 parts -10 parts of chitosan oligomer, 0.5 part -2 parts of Fructus Fici extract, 0.5 part -1 part of cajan seed extract,
0.5 part -1 part of Rhizoma Polygonati Odorati extract, 0.25 part -0.75 part of common perilla seed extract, 0.25 part -0.75 part of South Mountain boisiana extract.
2. a kind of pharmaceutical composition for being used to treat canker sore, it is characterised in that described pharmaceutical composition is by following parts by weight
The composition composition of proportioning：5 parts of chitosan oligomer, 1 part of Fructus Fici extract, 0.8 part of cajan seed extract, 0.8 part of Rhizoma Polygonati Odorati extract,
0.5 part of common perilla seed extract, 0.5 part of South Mountain boisiana extract.
3. a kind of preparation method for being used to treat the pharmaceutical composition of canker sore as claimed in claim 1 or 2, its feature exist
In this method is：Chitosan oligomer, Fructus Fici extract, cajan seed extract, Rhizoma Polygonati Odorati extract, common perilla seed extract, Wattakaka sinensis Stapf
Extract is mixed together with water, and being sufficiently stirred makes it uniformly boil 5min, be cooled to 25 DEG C ± 2 DEG C of room temperature, be filtered to remove insoluble
Thing, produce.
4. preparation method according to claim 3, it is characterised in that the dosage of the water is 5-15 times of raw material gross weight
Amount, preferably 10 times amounts.
5. preparation method according to claim 3, it is characterised in that the chitosan oligomer is prepared by the following method：
Chitosan 10g acetic acid 333ml are dissolved, chitosan concentration 0.03g/ml, add bromelain 5ml（Containing enzyme amount
40u）Hydrolysis, hydrolyze 20mim after adjust pH value to 6.0,50 DEG C continue degrade 5h, 100 DEG C of enzyme deactivation 15min, centrifuging and taking supernatant,
Freeze-drying, obtains chitosan oligomer 9.23g.
6. the preparation method according to claim 3 or 5, it is characterised in that the mean molecule quantity of the chitosan oligomer is
500-3000。
7. a kind of pharmaceutical composition as claimed in claim 1 is preparing the application in treating stomatocace medicine.
8. a kind of pharmaceutical composition for being used to treat canker sore as claimed in claim 2 is preparing treatment stomatocace medicine
In application.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610754644.9A CN107789480A (en) | 2016-08-30 | 2016-08-30 | A kind of pharmaceutical composition for being used to treat canker sore |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610754644.9A CN107789480A (en) | 2016-08-30 | 2016-08-30 | A kind of pharmaceutical composition for being used to treat canker sore |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107789480A true CN107789480A (en) | 2018-03-13 |
Family
ID=61529166
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610754644.9A Pending CN107789480A (en) | 2016-08-30 | 2016-08-30 | A kind of pharmaceutical composition for being used to treat canker sore |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107789480A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110711225A (en) * | 2019-11-29 | 2020-01-21 | 国泰振兴科技发展有限公司 | A pharmaceutical composition for treating oral ulcer, and its preparation method |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102727579A (en) * | 2011-04-11 | 2012-10-17 | 苏州瑞美科生物技术有限公司 | Pharmaceutical composition for treatment of oral ulcers |
| CN103356843A (en) * | 2012-03-28 | 2013-10-23 | 苏州瑞美科生物技术有限公司 | Chitosan oligosaccharide compound preparation and application thereof to preparation of drugs for treating skin ulcers |
| CN105596727A (en) * | 2016-01-09 | 2016-05-25 | 邢春红 | Radix polygonati officinalis containing mucopolysaccharide combination oral gel preparation and preparation method thereof |
-
2016
- 2016-08-30 CN CN201610754644.9A patent/CN107789480A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102727579A (en) * | 2011-04-11 | 2012-10-17 | 苏州瑞美科生物技术有限公司 | Pharmaceutical composition for treatment of oral ulcers |
| CN103356843A (en) * | 2012-03-28 | 2013-10-23 | 苏州瑞美科生物技术有限公司 | Chitosan oligosaccharide compound preparation and application thereof to preparation of drugs for treating skin ulcers |
| CN105596727A (en) * | 2016-01-09 | 2016-05-25 | 邢春红 | Radix polygonati officinalis containing mucopolysaccharide combination oral gel preparation and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 石宗珂，等: "治疗小儿口疮的经验", 《兰州医学院学报》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110711225A (en) * | 2019-11-29 | 2020-01-21 | 国泰振兴科技发展有限公司 | A pharmaceutical composition for treating oral ulcer, and its preparation method |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10251824B2 (en) | Method for inducing pluripotent stem cells and pluripotent stem cells prepared by said method | |
| KR100813914B1 (en) | The conversion and modification of natural medicines by intestinal probiotics co-fermentation cultures | |
| TWI598104B (en) | Use of Antrodia cinnamomea extract to improve side effects of chemotherapy | |
| CN101020715B (en) | Process of extracting and preparing deer nerve growth factor (DEER NGF) | |
| CN106265822A (en) | There are anti-inflammation raw myofunctional Mahonia bealei (Fort.) Carr. extract, preparation method and applications | |
| CN104367987A (en) | Astragalus mongholicus formulation for veterinary use and preparation method thereof | |
| CN102727579B (en) | A kind of pharmaceutical composition being used for the treatment of oral ulcer | |
| CN106834404B (en) | Enzymolysis polypeptide and application thereof in preparing medicament for treating lung adenocarcinoma | |
| CN102727581B (en) | A kind of pharmaceutical composition wound to repair | |
| KR100239946B1 (en) | The composition containing snapping turtle and tortoise, the preparation and the use thereof | |
| CN112790310A (en) | Saussurea involucrate polypeptide composite powder and preparation method thereof | |
| CN107789480A (en) | A kind of pharmaceutical composition for being used to treat canker sore | |
| CN102764294B (en) | Cough relieving and sputum eliminating combination and preparation method thereof | |
| CN101244074A (en) | Application of epimedium flavone and its effective component in preparing medicine for promoting nerve cell proliferation and differentiation | |
| CN115920005A (en) | Preparation method of chlorella protein polypeptide enteric sustained-release microcapsule | |
| CN109303787A (en) | It is a kind of for repairing the pharmaceutical composition of wound | |
| CN108219024B (en) | Calophyllum inophyllum flower polysaccharide, extraction method thereof and application thereof in preparing medicine for treating functional constipation | |
| CN104840747B (en) | Chinese medicine composition with antithyroid cancer activity and its preparation method and application | |
| CN101721437B (en) | Preparation method of medicine composition used for treating chronic pharyngitis | |
| CN110025643B (en) | Compound with anticancer activity and preparation method and application thereof | |
| CN111265594A (en) | Medicinal preparation for repairing wound and preparation method thereof | |
| CN102727577A (en) | Medicinal composition for treating gynecological inflammations | |
| CN107773724A (en) | A kind of pharmaceutical composition for being used to treat gynaecological imflammation | |
| CN113181229B (en) | Application of cabbage type rape-isatis tinctoria G monomer addition system in inhibiting novel coronavirus SARS-CoV-2 | |
| CN109350661B (en) | Fermented traditional Chinese medicine composition for relieving cough and reducing sputum and application thereof in preventing and treating porcine respiratory diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20180313 |